Beyond Cell Death: New Functions for TNF Family Cytokines in Autoimmunity and Tumor Immunotherapy.

Originally discovered as an inducer of apoptosis, the TNF-family receptor Fas (CD95, APO-1, TNFRSF6) has more recently been found to have functions beyond cell death, including T cell co-stimulation and promoting terminal differentiation of CD4+ and CD8+ T cells. Other TNF family members also discovered as apoptosis inducers, such as TRAIL (APO-2L, TNFSF10), can promote inflammation through caspase-8. Surprisingly, non-apoptotic signaling through Fas can protect from the autoimmunity seen in Fas deficiency independently from the cell death inducing functions of the receptor. Non-apoptotic Fas signaling can induce tumor cell growth and migration, and impair the efficacy of T cell adoptive immunotherapy. Blocking of non-apoptotic functions of these receptors may be a novel strategy to regulate autoimmunity and inflammation, and enhance antitumor immunity.

[1]  Enric Llorens-Bobadilla,et al.  CD95 in cancer: tool or target? , 2013, Trends in molecular medicine.

[2]  C. Klebanoff,et al.  Silencing stemness in T cell differentiation , 2018, Science.

[3]  Daniel Li,et al.  CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. , 2016, The Journal of clinical investigation.

[4]  L. Salmena,et al.  Requirement for Caspase-8 in NF-κB Activation by Antigen Receptor , 2005, Science.

[5]  F. Marincola,et al.  Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape , 2015, Cellular and Molecular Immunology.

[6]  C. Klebanoff,et al.  Sorting Through Subsets: Which T-Cell Populations Mediate Highly Effective Adoptive Immunotherapy? , 2012, Journal of immunotherapy.

[7]  C. Klebanoff,et al.  Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. , 2017, JCI insight.

[8]  Emad S. Alnemri,et al.  A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis , 2001, Nature.

[9]  Christian Stemberger,et al.  Novel Serial Positive Enrichment Technology Enables Clinical Multiparameter Cell Sorting , 2012, PloS one.

[10]  S. Steinberg,et al.  Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy , 2011, Clinical Cancer Research.

[11]  J. Sundberg,et al.  Elimination of antigen-presenting cells and autoreactive T cells by Fas contributes to prevention of autoimmunity. , 2007, Immunity.

[12]  Seamus J. Martin,et al.  Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas , 1995, Nature.

[13]  E. Yolcu,et al.  Engineering of bone marrow cells with fas-ligand protein-enhances donor-specific tolerance to solid organs. , 2011, Transplantation proceedings.

[14]  A. K. Srivastava,et al.  Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. , 2017, The Lancet. Oncology.

[15]  S. Ju,et al.  Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation , 1995, Nature.

[16]  Warren Strober,et al.  Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome , 1995, Cell.

[17]  I. Sancho-Martinez,et al.  Yes and PI3K bind CD95 to signal invasion of glioblastoma. , 2008, Cancer cell.

[18]  Mark S. Sundrud,et al.  Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. , 2015, Cancer research.

[19]  Guy S. Salvesen,et al.  Catalytic activity of the caspase-8-FLIPL complex inhibits RIPK3-dependent necrosis , 2011, Nature.

[20]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[21]  P. Muranski,et al.  Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. , 2013, The Journal of clinical investigation.

[22]  S. Rosenberg,et al.  Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice , 2011, Clinical Cancer Research.

[23]  Xiuli Wang,et al.  Regression of Glioblastoma after Chimeric Antigen Receptor T-Cell Therapy. , 2016, The New England journal of medicine.

[24]  M. Croft,et al.  Beyond TNF: TNF superfamily cytokines as targets for the treatment of rheumatic diseases , 2017, Nature Reviews Rheumatology.

[25]  W I Wood,et al.  Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. , 1997, Science.

[26]  S. Cullen,et al.  Fas/CD95-induced chemokines can serve as "find-me" signals for apoptotic cells. , 2013, Molecular cell.

[27]  M. Peter,et al.  Palmitoylation of CD95 facilitates formation of SDS‐stable receptor aggregates that initiate apoptosis signaling , 2007, The EMBO journal.

[28]  Masayuki Fukui,et al.  Pathogen-Associated Molecular Patterns Sensitize Macrophages to Fas Ligand-Induced Apoptosis and IL-1β Release1 , 2003, The Journal of Immunology.

[29]  F. Marincola,et al.  Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. , 2015, The Journal of clinical investigation.

[30]  M. Peter,et al.  CD95 ligand induces motility and invasiveness of apoptosis‐resistant tumor cells , 2004, The EMBO journal.

[31]  F. Marincola,et al.  Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. , 2016, Cell metabolism.

[32]  J. Gartner,et al.  T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer. , 2016, The New England journal of medicine.

[33]  L. Greller,et al.  Convergence of TCR and cytokine signaling leads to FOXO3a phosphorylation and drives the survival of CD4+ central memory T cells , 2007, The Journal of experimental medicine.

[34]  Seamus J. Martin,et al.  Caspase-8 Acts in a Non-enzymatic Role as a Scaffold for Assembly of a Pro-inflammatory "FADDosome" Complex upon TRAIL Stimulation. , 2017, Molecular cell.

[35]  G. Stark,et al.  NFκB-dependent signaling pathways , 2002 .

[36]  L. Hurton,et al.  Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells , 2016, Proceedings of the National Academy of Sciences.

[37]  S. Yonehara,et al.  Fas-Mediated Inflammatory Response in Listeria monocytogenes Infection , 2013, The Journal of Immunology.

[38]  B. A. Aksoy,et al.  PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells , 2017, Front. Immunol..

[39]  H. Kidoya,et al.  Involvement of IL-17 in Fas ligand-induced inflammation. , 2004, International immunology.

[40]  F. Ramsdell,et al.  Fas transduces activation signals in normal human T lymphocytes , 1993, The Journal of experimental medicine.

[41]  N. Restifo Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape , 2000, Nature Medicine.

[42]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[43]  M. Essig,et al.  Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury , 2004, Nature Medicine.

[44]  S. Rosenberg,et al.  Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  L. Salmena,et al.  Caspase-8 deficiency in T cells leads to a lethal lymphoinfiltrative immune disorder , 2005, The Journal of experimental medicine.

[46]  M. Peter,et al.  Resistance of cultured peripheral T cells towards activation‐induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death‐inducing signaling complex , 1997, European journal of immunology.

[47]  S. Steinberg,et al.  Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[48]  S. Ghosh,et al.  Crosstalk in NF-κB signaling pathways , 2011, Nature Immunology.

[49]  Martin Pule,et al.  Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. , 2011, Blood.

[50]  C. Turtle,et al.  Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells. , 2012, Blood.

[51]  P. Kiener,et al.  Fas (CD95) Induces Proinflammatory Cytokine Responses by Human Monocytes and Monocyte-Derived Macrophages12 , 2003, The Journal of Immunology.

[52]  R. Hakem,et al.  RIP3 mediates the embryonic lethality of caspase-8-deficient mice , 2011, Nature.

[53]  S. Mukai,et al.  A novel treatment for ocular tumors using membrane FasL vesicles to activate innate immunity and terminate immune privilege. , 2005, Investigative ophthalmology & visual science.

[54]  B. Aggarwal Signalling pathways of the TNF superfamily: a double-edged sword , 2003, Nature Reviews Immunology.

[55]  J. Wigginton,et al.  Lack of FasL-mediated killing leads to in vivo tumor promotion in mouse Lewis lung cancer , 2003, Apoptosis.

[56]  R. Siegel,et al.  The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity , 2000, Nature Immunology.

[57]  S. Rosenberg,et al.  Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer , 2014, Science.

[58]  J. Wrangle,et al.  β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity. , 2017, JCI insight.

[59]  Arnold Munnich,et al.  TAB2, TRAF6 and TAK1 are involved in NF-kappaB activation induced by the TNF-receptor, Edar and its adaptator Edaradd. , 2005, Human molecular genetics.

[60]  F. Marincola,et al.  A human memory T-cell subset with stem cell-like properties , 2011, Nature Medicine.

[61]  S. Ju,et al.  Fas Ligand Engagement of Resident Peritoneal Macrophages In Vivo Induces Apoptosis and the Production of Neutrophil Chemotactic Factors1 , 2001, The Journal of Immunology.

[62]  C. Klebanoff,et al.  Paths to stemness: building the ultimate antitumour T cell , 2012, Nature Reviews Cancer.

[63]  B. Ksander,et al.  Membrane Fas Ligand Activates Innate Immunity and Terminates Ocular Immune Privilege1 , 2002, The Journal of Immunology.

[64]  M. Lenardo lnterleukin-2 programs mouse αβ T lymphocytes for apoptosis , 1991, Nature.

[65]  J. Friedberg,et al.  Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  J. Heath,et al.  A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication , 2018, PloS one.

[67]  Sadik H. Kassim,et al.  A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response , 2014, Clinical Cancer Research.

[68]  D. Lawrence,et al.  Molecular Determinants of Kinase Pathway Activation by Apo2 Ligand/Tumor Necrosis Factor-related Apoptosis-inducing Ligand* , 2005, Journal of Biological Chemistry.

[69]  T. Waldmann,et al.  Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[70]  P. Krammer,et al.  Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) , 1995, Nature.

[71]  S. Nagata,et al.  Caspase 1-independent IL-1β release and inflammation induced by the apoptosis inducer Fas ligand , 1998, Nature Medicine.

[72]  Yelena L. Pobezinskaya,et al.  The role of TRADD in death receptor signaling , 2012, Cell cycle.

[73]  H. Blau,et al.  Immune response and myoblasts that express Fas ligand. , 1997, Science.

[74]  D. Maloney,et al.  Accepted Article Preview : Published ahead of advance online publication , 2016 .

[75]  R. Levy,et al.  Axicabtagene Ciloleucel CAR T‐Cell Therapy in Refractory Large B‐Cell Lymphoma , 2017, The New England journal of medicine.

[76]  H. Ford,et al.  TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[77]  F. Martinon,et al.  The caspase-8 inhibitor FLIP promotes activation of NF-κB and Erk signaling pathways , 2000, Current Biology.

[78]  D. Green,et al.  FADD and Caspase-8 Mediate Priming and Activation of the Canonical and Noncanonical Nlrp3 Inflammasomes , 2014, The Journal of Immunology.

[79]  J. Tschopp,et al.  Induction of TNF Receptor I-Mediated Apoptosis via Two Sequential Signaling Complexes , 2003, Cell.

[80]  S. Rosenberg,et al.  Prospects for gene-engineered T cell immunotherapy for solid cancers , 2016, Nature Medicine.

[81]  J. Tschopp,et al.  Caspase Activation Is Required for T Cell Proliferation , 1999, The Journal of experimental medicine.

[82]  Christine Feig,et al.  CD95/Fas promotes tumour growth , 2010, Nature.

[83]  P. Muranski,et al.  Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells , 2009, Nature Medicine.

[84]  J. Pichler,et al.  A Phase II, Randomized, Study of Weekly APG101+Reirradiation versus Reirradiation in Progressive Glioblastoma , 2014, Clinical Cancer Research.

[85]  G. Nabel,et al.  Regulation of the proinflammatory effects of Fas ligand (CD95L). , 1998, Science.

[86]  J. Lippincott-Schwartz,et al.  Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction , 2016, Nature Communications.

[87]  D. Green,et al.  Cutting Edge: FAS (CD95) Mediates Noncanonical IL-1β and IL-18 Maturation via Caspase-8 in an RIP3-Independent Manner , 2012, The Journal of Immunology.

[88]  C. Creighton,et al.  Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. , 2014, Blood.

[89]  K. Davis,et al.  Tisagenlecleucel in Children and Young Adults with B‐Cell Lymphoblastic Leukemia , 2018, The New England journal of medicine.

[90]  B. Howie,et al.  Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer , 2017, Science.

[91]  E. Simpson,et al.  An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow , 1998, Nature Medicine.

[92]  Petra Reinke,et al.  Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody–Activated Chimeric Antigen Receptor–Modified T Cells , 2017, The Journal of Immunology.

[93]  Xuetao Cao,et al.  Fas ligation induces IL-1β-dependent maturation and IL-1β-independent survival of dendritic cells: different roles of ERK and NF-κB signaling pathways , 2003 .

[94]  J. Goverman,et al.  T cell deletion in high antigen dose therapy of autoimmune encephalomyelitis. , 1994, Science.

[95]  R. Siegel,et al.  Harnessing programmed cell death as a therapeutic strategy in rheumatic diseases , 2011, Nature Reviews Rheumatology.

[96]  Lieping Chen,et al.  Molecular mechanisms of T cell co-stimulation and co-inhibition , 2013, Nature Reviews Immunology.

[97]  D. Marguet,et al.  Palmitoylation is required for efficient Fas cell death signaling , 2007, The EMBO journal.

[98]  S. Price,et al.  Specific elimination of effector memory CD4+ T cells due to enhanced Fas signaling complex formation and association with lipid raft microdomains , 2011, Cell Death and Differentiation.

[99]  T. Speed,et al.  Distinct epigenetic signatures delineate transcriptional programs during virus-specific CD8(+) T cell differentiation. , 2014, Immunity.

[100]  R. Grossman,et al.  HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial , 2017, JAMA oncology.

[101]  T. Gajewski On the TRAIL toward death receptor-based cancer therapeutics. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[102]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[103]  J. Puck,et al.  Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency , 2002, Nature.

[104]  K. Rajewsky,et al.  Fas receptor expression in germinal-center B cells is essential for T and B lymphocyte homeostasis. , 2008, Immunity.

[105]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[106]  N. Copeland,et al.  Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis , 1992, Nature.

[107]  K. Elkon,et al.  Dendritic cells are resistant to apoptosis through the Fas (CD95/APO-1) pathway. , 1999, Journal of immunology.

[108]  Elizabeth A. Kruse,et al.  Membrane-bound Fas ligand only is essential for Fas-induced apoptosis , 2009, Nature.

[109]  S. Grupp,et al.  Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy. , 2014, Cytotherapy.

[110]  S. Berger,et al.  Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade , 2016, Science.

[111]  M. Peter,et al.  The CD95(APO-1/Fas) DISC and beyond , 2003, Cell Death and Differentiation.

[112]  Peter Scheurich,et al.  NFκB activation by Fas is mediated through FADD, caspase-8, and RIP and is inhibited by FLIP , 2004, The Journal of cell biology.